CBI Takes Over Investigation of Multi-Crore Fake Drug Manufacturing Racket in Puducherry
The Central Bureau of Investigation (CBI) has officially registered a case against three individuals in connection with a massive fake drug manufacturing racket operating in Puducherry, which is estimated to be worth several crores of rupees. This action follows a formal communication from Puducherry's Special Secretary (Home), R Kesavan, requesting the agency to take over the investigation into the widespread counterfeit pharmaceutical operations within the Union Territory.
Accused Individuals and Charges Filed
The agency has booked Vivek Venkatesan, aged 32, from Amman Pharma; N Raja, also known as Valliappan, aged 44, from Reddiarpalayam; and A K Rana from Meenakshi Pharma. They face serious charges including criminal conspiracy, adulteration of drugs, cheating, illegal manufacture and sale of drugs, and distribution of spurious drugs. The CBI has invoked sections 61, 276, and 318 (4) of the Bharatiya Nyaya Sanhita (BNS), along with sections 27 (d) and 17 B (b) of the Drugs and Cosmetics Act, 1940, to prosecute the accused.
Background of the Racket and Initial Bust
Last year, the Puducherry Drugs Controlling Authority, in collaboration with the Puducherry CB-CID, conducted raids on multiple fake drug manufacturing units and godowns. During these operations, authorities seized large quantities of spurious drugs and subsequently sealed the premises. It was discovered that these illicit units had been producing counterfeit medications under the names of registered pharmaceutical brands and marketing them extensively across the country.
The authority promptly alerted Lupin Ltd, based in Chennai, after identifying that several fake pharma units were manufacturing spurious or counterfeit drugs using Lupin's registered brand names. This fraudulent activity involved replicating packaging, labelling, trademarks, artwork, and batch numbering patterns to deceive consumers and healthcare providers.
Complaint from Lupin Ltd and Health Risks
B Bakkiyaraj, the manager of Lupin Ltd in Chennai, lodged a formal complaint with the CB-CID, detailing how the seized drugs were fraudulent imitations of Lupin's legitimate products. The complaint highlighted that these acts constituted cheating, counterfeiting, forgery, and the misuse of false copyrights, all carried out with dishonest intentions to mislead the public.
Such deceptive practices pose severe risks to human life, as the quality, potency, and safety of these spurious drugs are entirely unknown. Consumption of these counterfeit medications could lead to serious adverse health consequences, including treatment failures, toxicity, or even fatalities, underscoring the critical nature of this investigation.
Previous Arrests and Ongoing Legal Proceedings
Prior to the CBI's involvement, the CB-CID had initiated inquiries into the racket, resulting in the arrest of more than a dozen individuals. Among those arrested was a former Indian Forest Service (IFS) officer, indicating the potential involvement of individuals with significant backgrounds. However, all arrested persons have since been released on bail, pending further legal proceedings.
The CBI's takeover marks a significant escalation in the efforts to dismantle this dangerous network and ensure that those responsible are held accountable under the law. The agency is now spearheading a comprehensive investigation to uncover the full extent of the racket, including its supply chains and financial dealings.
